Exelixis, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Exelixis, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Exelixis, Inc.. The Group's principal activity is to develop innovative therapies for cancer and other serious diseases. Its pharmaceutical programs focuses on discovery and development of small molecule drugs for cancer. The Gruoup has built a multidisciplinary, integrated research and development platform that supports the complex, iterative nature of drug discovery, translational research and clinical development. Its first-generation anticancer product candidates in our clinical pipeline are Spectrum Selective Kinase Inhibitors, that have been optimized for balanced potency, specificity, tolerability and pharmacologic parameters. It operates in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report